Intake of Lactobacillus reuteri Improves Incretin and Insulin Secretion in Glucose-Tolerant Humans: A Proof of Concept
- 2015-06-17
- Diabetes Care 38(10)
- M. Simon
- K. Strassburger
- B. Nowotny
- H. Kolb
- P. Nowotny
- V. Burkart
- F. Zivehe
- J. Hwang
- P. Stehle
- G. Pacini
- B. Hartmann
- J. Holst
- C. Mackenzie
- L. Bindels
- I. Martínez
- J. Walter
- B. Henrich
- N. Schloot
- M. Roden
- PubMed: 26084343
- DOI: 10.2337/dc14-2690
Abstract
Objective: Ingestion of probiotics can modify gut microbiota and alter insulin resistance and diabetes development in rodents. We hypothesized that daily intake of Lactobacillus reuteri increases insulin sensitivity by changing cytokine release and insulin secretion via modulation of the release of glucagon-like peptides (GLP)-1 and -2.
Research design and methods: A prospective, double-blind, randomized trial was performed in 21 glucose-tolerant humans (11 lean: age 49 ± 7 years, BMI 23.6 ± 1.7 kg/m(2); 10 obese: age 51 ± 7 years, BMI 35.5 ± 4.9 kg/m(2)). Participants ingested 10(10) b.i.d. L. reuteri SD5865 or placebo over 4 weeks. Oral glucose tolerance and isoglycemic glucose infusion tests were used to assess incretin effect and GLP-1 and GLP-2 secretion, and euglycemic-hyperinsulinemic clamps with [6,6-(2)H2]glucose were used to measure peripheral insulin sensitivity and endogenous glucose production. Muscle and hepatic lipid contents were assessed by (1)H-magnetic resonance spectroscopy, and immune status, cytokines, and endotoxin were measured with specific assays.
Results: In glucose-tolerant volunteers, daily administration of L. reuteri SD5865 increased glucose-stimulated GLP-1 and GLP-2 release by 76% (P < 0.01) and 43% (P < 0.01), respectively, compared with placebo, along with 49% higher insulin (P < 0.05) and 55% higher C-peptide secretion (P < 0.05). However, the intervention did not alter peripheral and hepatic insulin sensitivity, body mass, ectopic fat content, or circulating cytokines.
Conclusions: Enrichment of gut microbiota with L. reuteri increases insulin secretion, possibly due to augmented incretin release, but does not directly affect insulin sensitivity or body fat distribution. This suggests that oral ingestion of one specific strain may serve as a novel therapeutic approach to improve glucose-dependent insulin release.
Trial registration: ClinicalTrials.gov NCT01250106.
Research Insights
Supplement | Health Outcome | Effect Type | Effect Size |
---|---|---|---|
Lactobacillus reuteri | Enhanced Insulin Secretion | Beneficial | Moderate |
Lactobacillus reuteri HA-188 | Enhanced GLP-1 Secretion | Beneficial | Large |
Lactobacillus reuteri HA-188 | Enhanced GLP-2 Secretion | Beneficial | Large |
Lactobacillus reuteri HA-188 | Enhanced Insulin Secretion | Beneficial | Moderate |
Lactobacillus reuteri HA-188 | Increased C-Peptide Secretion | Beneficial | Moderate |
Lactobacillus reuteri HA-188 | No Change in Circulating Cytokines | Neutral | Small |
Lactobacillus reuteri HA-188 | No Change in Ectopic Fat Content | Neutral | Small |
Lactobacillus reuteri HA-188 | Stable Body Mass | Neutral | Small |
Lactobacillus reuteri HA-188 | Unchanged Insulin Sensitivity | Neutral | Small |
Lactobacillus reuteri LRE02 | Enhanced Insulin Secretion | Beneficial | Moderate |
Lactobacillus reuteri MAK02L14R | Enhanced Insulin Secretion | Beneficial | Moderate |
Lactobacillus reuteri NCIMB 30242 | Enhanced Insulin Secretion | Beneficial | Moderate |
Lactobacillus reuteri Osfortis | Enhanced Insulin Secretion | Beneficial | Moderate |
Lactobacillus reuteri Osfortis | Unchanged Insulin Sensitivity | Neutral | Small |
Lactobacillus reuteri RC-14 | Enhanced Insulin Secretion | Beneficial | Moderate |
Lactobacillus reuteri RC-14 | Increased C-Peptide Secretion | Beneficial | Moderate |
Lactobacillus reuteri RC-14 | No Change in Circulating Cytokines | Neutral | Small |
Lactobacillus reuteri RC-14 | No Change in Ectopic Fat Content | Neutral | Small |
Lactobacillus reuteri RC-14 | Stable Body Mass | Neutral | Small |
Lactobacillus reuteri RC-14 | Unchanged Insulin Sensitivity | Neutral | Small |
Lactobacillus reuteri SD-5865 | Enhanced Insulin Secretion | Beneficial | Moderate |
Lactobacillus reuteri SD-5865 | Increased C-Peptide Secretion | Beneficial | Moderate |
Lactobacillus reuteri SD-5865 | Increased GLP-2 Release | Beneficial | Large |
Lactobacillus reuteri SD-5865 | Increased Intestinal GLP-1 Levels | Beneficial | Large |
Lactobacillus reuteri SD-5865 | No Change in Circulating Cytokines | Neutral | Small |
Lactobacillus reuteri SD-5865 | No Change in Ectopic Fat Content | Neutral | Small |
Lactobacillus reuteri SD-5865 | Stable Body Mass | Neutral | Small |
Lactobacillus reuteri SD-5865 | Unchanged Insulin Sensitivity | Neutral | Small |
Lactobacillus reuteri UALg-05 | Enhanced Insulin Secretion | Beneficial | Moderate |
Lactobacillus reuteri UALg-05 | Unchanged Insulin Sensitivity | Neutral | Small |
Lactobacillus reuteri UALre-16 | Enhanced Insulin Secretion | Beneficial | Moderate |
Lactobacillus reuteri UALre-16 | Improved Incretin Release | Beneficial | Moderate |